Trial
NCT03240861
Genetically Engineered PBMC and PBSC Expressing NY-ESO-1 TCR After a Myeloablative Conditioning Regimen to Treat Patients With Advanced Cancer
Phase ITERMINATEDOPERATIONALConfidence: HIGH
Sponsor
Jonsson Comprehensive Cancer Center
Collaborators
California Institute for Regenerative Medicine (CIRM)
Condition
HLA-A*0201 Positive Cells Present
Intervention
18F-FHBG
Why stopped
slow accrual
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2023-11-01